m6A-centered Disease Response Information
General Information of the Disease (ID: M6ADIS0028)
Name |
Thymoma
|
||||
---|---|---|---|---|---|
ICD |
ICD-11: 2C27
|
Full List of Target Gene(s) of This m6A-centered Disease Response
Metastasis associated lung adenocarcinoma transcript 1 (MALAT1)
In total 2 item(s) under this target gene | ||||
Experiment 1 Reporting the m6A-centered Disease Response by This Target Gene | [1] | |||
Response Summary | This study highlighted METTL3 as a tumor promoter in Thymic tumors and c-MYC as a promising target to be exploited for the treatment of TET. High expression of c-MYC protein is enabled by lncRNA Metastasis associated lung adenocarcinoma transcript 1 (MALAT1), which is methylated and delocalized by METTL3. Silencing of METTL3 combined with cisplatin or c-MYC inhibitor induces cell death in TET cells. Blocking of c-MYC by using JQ1 inhibitor cooperates with METTL3 depletion in the inhibition of proliferation and induction of cell death. | |||
Responsed Disease | Thymic epithelial tumors [ICD-11: 2C27.Y] | |||
Responsed Drug | Cisplatin | Approved | ||
Target Regulator | Methyltransferase-like 3 (METTL3) | WRITER | ||
Target Regulation | Up regulation | |||
Pathway Response | Cellular senescence | hsa04218 | ||
Cell Process | Cell viability and proliferation | |||
In-vitro Model | T1889 | Thymic undifferentiated carcinoma | Homo sapiens | CVCL_D024 |
Experiment 2 Reporting the m6A-centered Disease Response by This Target Gene | [1] | |||
Response Summary | This study highlighted METTL3 as a tumor promoter in Thymic tumors and c-MYC as a promising target to be exploited for the treatment of TET. High expression of c-MYC protein is enabled by lncRNA Metastasis associated lung adenocarcinoma transcript 1 (MALAT1), which is methylated and delocalized by METTL3. Silencing of METTL3 combined with cisplatin or c-MYC inhibitor induces cell death in TET cells. Blocking of c-MYC by using JQ1 inhibitor cooperates with METTL3 depletion in the inhibition of proliferation and induction of cell death. | |||
Responsed Disease | Thymic epithelial tumors [ICD-11: 2C27.Y] | |||
Responsed Drug | JQ-1 | Phase 1 | ||
Target Regulator | Methyltransferase-like 3 (METTL3) | WRITER | ||
Target Regulation | Up regulation | |||
Pathway Response | Cellular senescence | hsa04218 | ||
Cell Process | Cell viability and proliferation | |||
In-vitro Model | T1889 | Thymic undifferentiated carcinoma | Homo sapiens | CVCL_D024 |